To OTC Journal Members: 
 

This Is Really Big- DCA

I've done a little more research and I'm now more convinced than ever that yesterday's penny stock idea- VRAL- has huge upside potential. I've looked into this DCA Cancer Therapy a bit further, and gotten a better understanding of the value.

This is my first big winner of the last few ideas, and those that acted on it yesterday are seeing the KACHING!!! Here's the chart:

VRAL is now up a full 50% from yesterday's entry level of $.02- as I said- it can be quite easy to notch nice gains in these really low priced ideas.

The market is starting to buzz about yesterday's DCA announcement. I've done my research, and now understand why it's so big. DCA- Dichloroacetate- is a metabolic disrupter. DCA is a non toxic chemical. It inteferes with the way cancer cells metabolize, and causes them to starve and subsequently die.

A number of major news outlets have covered DCA- accusing Big Pharma of ignoring the potential of DCA as it might be a simple way to treat cancer, and cost big pharma billions.

Evangelos Michelakis, a cancer researcher at the University of Alberta, discovered the compound and had encouraging results in the lab. Dr. Daniel Chang at Stanford Cancer Center is looking at is as well.

The compound was heretofore considered "unpatenable"- and therefore had limited commercial value.

Yesterday's annoucement, for those that understand it, is huge. Dr. Karen Newell's use of DCA has been officially granted a patent- US Patent office grant #8,071,646- to be issued on 12/6/2011.

This is huge stuff, particularly when you marry in Marshall Phelps, and advisor to VRAL. Phelps was formerly the Corporate Vice President at Microsoft in charge of Intellectual Property and Licensing.

Now that DCA has a patent, it a license or co development agreement with a major player has a lot of value. Hence, the surge in stock price.

Could be headed for much higher levels.

Home Page : www.otcjournal.com
Email Questions or Comments To: editor@otcjournal.com